Found 24 matching trials
Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer PHASE2 Abbreviated Title: Neoadjuvant FOLFIRINOX combined with Pembrolizumab follo...
Show More Location
Baylor College of Medicine
Learn More & Join Trial
Neoadjuvant Modified FOLFIRINOX and Stereotactic Body Radiation Therapy in Borderline Resectable Pancreatic Adenocarcinoma PHASE2 Surgical resection is the only potentially curative treatment for patients ...
Show More Location
Smilow Cancer Hospital
Learn More & Join Trial
AG vs mFOLFIRINOX as Neoadjuvant Therapy for Borderline Reseactable and Locally Advanced Pancreatic Cancer PHASE3 This is a prospective, single-center, randomized, controlled phase โ
ข study....
Location
Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University
Learn More & Join Trial
Sequential Use of AG and mFOLFIRINOX as Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer PHASE3 The prognosis of pancreatic cancer is extremely poor. Current guidelines re...
Show More Location
The second affiliated hospital of Zhejiang University
Learn More & Join Trial
PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP (PRISM-TAMP) PHASE1 Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with poor s...
Show More Location
University of Vermont Medical Center
Learn More & Join Trial
A Phase 2 Trial of Neoadjuvant Modified FOLFIRINOX Chemotherapy for Resectable Pancreatic Adenocarcinoma PHASE2 Within the next decade, pancreatic ductal adenocarcinoma (PDAC) is expected...
Show More Location
Division of Medical Oncology, Yonsei Cancer Center, Yonsei Univ. College of Medicine, Korea
Learn More & Join Trial
Modified-FOLFIRINOX Regimen Based Neoadjuvant Therapy in Chinese Patients With Locally Advanced Pancreatic Cancer N/A FOLFIRINOX regimen is first-line neoadjuvant chemotherapies for patients wi...
Show More Location
the second affiliated hospital of Zhejiang University
Learn More & Join Trial
NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer PHASE2 This phase II trial evaluates whether early switching from modified fluorou...
Show More Status
Active Not Recruiting
Location
OHSU Knight Cancer Institute
Learn More & Join Trial
Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer PHASE2 This is a research study to evaluate how the genetic makeup of Pancreatic D...
Show More Location
University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center
Learn More & Join Trial
Prospective Cohort of Patients Treated Using Neoadjuvant Modified FOLFIRINOX 6 Cycles for Potentially Resectable Pancreatic Duct Adenocarcinoma, Candidate for Participation in the PANACHE02 Clinical Trial N/A The aim of our study is to build up biological, radiological and tissue col...
Show More Learn More & Join Trial